Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Intranasal Placebo
DRUG: Midazolam Placebo Solution
DRUG: Midazolam
DRUG: Esketamine
DRUG: Esketamine
DRUG: Esketamine

Sponsor

Janssen Research & Development, LLC